In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.
|Journal||Journal of Diabetes and Its Complications|
|Early online date||29 Sept 2021|
|Publication status||Published - Dec 2021|